Intima Media Thickness Regression in Dyslipidemic Teenagers
NCT ID: NCT01768481
Last Updated: 2013-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
16 participants
INTERVENTIONAL
2004-01-31
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Atorvastatin for Reduction of Myocardial Damage During Angiography and Its Mechanism Associated With IMR
NCT01761656
Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease
NCT00770575
This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.
NCT00380939
Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease
NCT00917527
Effect of Acute Statin Treatment in Patients Undergoing Percutaneous Coronary Intervention
NCT00588471
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Statin
Atorvastatin 10 mg every day for one year
Atorvastatin
10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year
Sugar pill
Same size, taste and size placebo tablet (manufactured by sponsor) given every day for one year.
sugar pill
placebo controlled arm receives similarly looking placebo.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year
sugar pill
placebo controlled arm receives similarly looking placebo.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Abnormal Triglyceride levels (\>1.7mmol/L).
* Abnormal HDL-C levels (1.0mmol/L)
Exclusion Criteria
* Diabetes
14 Years
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Université de Montréal
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Laurent Legault
associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laurent Legault, MD
Role: PRINCIPAL_INVESTIGATOR
Hopital Maisonneuve-Rosemont, UMontreal
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HMR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.